147471-13-4

Upstream product

• 288-32-4 1H-imidazole 
• 115621-60-8 4-(4-fluoro-3-nitrophenyl)-1,5-dihydro-3-methyl-2H-pyrrol-2-one 
• 115621-56-2 4-(4-fluorophenyl)-1,5-dihydro-1-(4-methoxyphenyl)-3-methyl-2H-pyrrol-2-one 
• 115653-72-0 4-(4-fluorophenyl)-1,5-dihydro-1-(4-methoxyphenyl)-2H-pyrrol-2-one 
• 147471-19-0 (E)-3-(4-fluorophenyl)-2-butenoic acid ethyl ester 
• 115621-58-4 4-(4-fluorophenyl)-1,5-dihydro-3-methyl-2H-pyrrol-2-one 
• 403-42-9 1-(4-fluorophenyl)ethanone 

Downstream Products

• 115621-49-3 1,5-dihydro-4-[4-(1 H-imidazol-1-yl)phenyl]-3-methyl-2 H-pyrrol-2-one 
• 1027537-61-6 4-[3-amino-4-(1H-imidazol-1-yl)phenyl]-1,5-dihydro-3-methyl-2H-pyrrol-2-one 

Relevant academic research and scientific papers

(Imidazolylphenyl)pyrrol-2-one inhibitors of cardiac cAMP phosphodiesterase

Seven 3-alkyl-4-aryl-1,5-dihydro-2H-pyrrol-2-ones were prepared as potential inhibitors of cardiac cAMP phosphodiesterase (PDE). The design of these compounds made use of rolipram, a known inhibitor of the brain cAMP PDE isozyme, as a lead structure and w

Cardiotonic imidazolylphenylpyrrol-2-ones

Novel imidazolylphenylpyrrol-2-ones are described as having cardiovascular properties especially as cardiotonic agents in the treatment of congestive heart failure. Pharmaceutical formulations containing such compounds are also described.